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Letter
TO THE EDITOR: Chahine, Karaoui, and Mansour1 
reviewed the efficacy and safety of bedaquiline in the treat-
ment of adults with pulmonary multidrug-resistant tuberculo-
sis (MDR-TB) and generally agree with the comments made 
by Kakkar and Dahiya.2 Bedaquiline was approved by the 
Food and Drug Administration based largely on results from 
phase 2 studies using sputum conversion as a surrogate 
marker for efficacy rather than long-term mortality data.2 
Bedaquiline was shown to be associated with an unfavorable 
side effect profile, including an unexplained increased risk of 
mortality, QT prolongation, and elevated liver function tests.2 
However, it is important to acknowledge that bedaquiline is 
the first novel drug to be approved for the treatment of TB in 
more than 4 decades and the communities devastated by 
MDR-TB are in desperate need for more options to manage 
their patients. Initial reports describing the use of bedaquiline 
in patients with MDR-TB and extensively drug-resistant TB 
are promising.3,4 Fortunately, the World Health Organization 
(WHO) has recently issued an interim policy guidance rec-
ommending that bedaquiline may be added to a WHO-
recommended regimen in adult patients with MDR-TB when 
an effective regimen containing 4 second-line drugs in addi-
tion to pyrazinamide cannot be designed, and when there is 
documented evidence of resistance to any fluoroquinolone in 
addition to multidrug resistance.5 Similarly, the Centers for 
Disease Control and Prevention (CDC) has also issued provi-
sional guidelines recommending that bedaquiline may be 
used for 24 weeks in adults with laboratory-confirmed pul-
monary MDR-TB when an effective regimen cannot other-
wise be provided; on a case-by-case basis in children, persons 
with HIV, pregnant women, persons with extrapulmonary 
MDR-TB, and patients with comorbidties when effective 
regimen cannot otherwise be provided; and on a case-by-case 
basis for durations longer than 24 weeks when an effective 
regimen cannot be provided.6 Both WHO and CDC empha-
size the need for careful monitoring of patients on bedaqui-
line therapy for safety concerns.5,6
Until further data become available, the authors believe 
that patients who meet eligible criteria according to cur-
rent guidelines may benefit from bedaquiline therapy with 
careful monitoring for potential side effects and drug 
interactions.
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